U.S. pharmaceutical company Eli Lilly plans to disclose the topline results of its phase 3 clinical trial for remternemab, a new drug candidate developed as a successor to its Alzheimer’s treatment ...

Discovery could redirect drug development for disease affecting 6.7 million Americans The two AMPKα isoforms can have ...

Scientists behind the study say that if the harmful influence of the gene could be neutralised, up to three-quarters - and ...

Potentially more than 90% of Alzheimer's disease cases would not occur without the contribution of a single gene (APOE), ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

The FDA has accepted an investigational new drug application for an investigational and proprietary combination therapy to ...

If you’re a woman of a certain age, your social media feed may be filled with claims that a single therapy will fight ...

A new study found that fixing energy balance in the brain reversed symptoms of advanced Alzheimer’s in mice.  Researchers ...

You think you’re fine. Your family and friends think you’re fine. But, just maybe, you’re not. Maybe you already have Alzheimer’s disease, but you just don’t know it yet, because it can begin ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

New safety study links sedative use to increased stroke risk. A large UK study involving more than 165,000 people with dementia has found that the drug risperidone increases the risk of stroke in all ...